Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02273596 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety Study of WTX101 (ALXN1840) in Adult Wilson Disease Patients
A Phase 2 study, sponsored by Alexion Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 29
- Enrollment target
NCT02273596 is a Phase 2 study that has completed, run by Alexion Pharmaceuticals. The registered enrollment target is 29 participants.
The verdict
NCT02273596, a Phase 2 study, has completed, sponsored by Alexion Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 29 participants
- Enrollment target
Study Summary
The main purpose of the study was to evaluate the efficacy of ALXN1840 (formerly WTX101) for 24 weeks on non-ceruloplasmin-bound copper (NCC) concentrations adjusted for molybdenum plasma concentration in participants newly diagnosed with Wilson Disease (WD) who were aged 18 and older and who had NCC concentrations within or above the reference range at the time of enrollment in the study. The study consisted of a 24-week Treatment Period, followed by a planned 36-month Extension Period.
Interventions
- DRUG ALXN1840
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2014-11-24 |
| Est. Completion | 2018-11-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02273596
The ClinicalTrials.gov registry entry for NCT02273596 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alexion Pharmaceuticals, which has 162 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ALXN1840 is the first listed.
NCT02273596 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02273596 about?
NCT02273596 is a clinical study titled "Efficacy and Safety Study of WTX101 (ALXN1840) in Adult Wilson Disease Patients". The main purpose of the study was to evaluate the efficacy of ALXN1840 (formerly WTX101) for 24 weeks on non-ceruloplasmin-bound copper (NCC) concentrations adjusted for molybdenum plasma concentration in participants newly diagnosed with Wilson Disease (WD) who were aged 18 and older and who had NC...
What is the current status of trial NCT02273596?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 29 participants. The study started on 2014-11-24. Estimated completion is 2018-11-07.
What interventions are being tested in trial NCT02273596?
The interventions under investigation include: ALXN1840 (DRUG).
Who is sponsoring clinical trial NCT02273596?
This trial is sponsored by Alexion Pharmaceuticals, which has 162 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.